Gene electrotransfer refers to gene transfection by electroporation and is an effective non-viral method for delivering naked DNA into cells and tissues. This study presents data from gene electrotransfer with erythropoietin (EPO) to mouse skin. Nine-week-old female NMRI mice received one, two or three intradermal injections of 50 mg EPO plasmid and were subsequently electroporated. With plate electrodes and 100 mg of EPO, a significant increase in hemoglobin (Po0.01) was observed compared with controls. The level of hemoglobin peaked after 5 weeks but stayed significantly elevated for more than 3 months. Serum EPO was significantly increased (Po0.001) 24 h after the transfection and remained significantly different compared with controls until the maximum level of serum EPO was reached after 2 weeks. Eight weeks after the transfection serum EPO returned to baseline. In this study, we have established that gene electrotransfer to skin of even small amounts of DNA can lead to systemically therapeutic levels of protein. This means that in addition to DNA vaccinations, there is a potential utility for electroporation in alleviating systemic diseases such as cancer and protein deficiency disorders.
Introduction
Gene therapy is increasingly being considered when new ways of treating and hopefully curing serious diseases such as cancer are explored. 1 A vast amount of studies have encompassed viral vectors and non-viral methods such as naked DNA injections, 2,3 liposomes 4,5 and the use of gene guns. 6 Theoretically gene therapy can be divided into three different approaches:
(a) Single cell approach, for example, ex vivo transfection of keratinocytes with the purpose of correcting laminin-5 deficiency in patients with junctional epidermolysis bullosa. 7 Every single cell in a given population must be transfected to benefit from the modification of the gene. transfection to tumor cells. In that case it is not necessary to transfect every single cell, though a threshold has to be reached to obtain the paracrine effect of the transgene. (c) Systemic approach; for example, erythropoietin (EPO) 10 or metargidin 11 to muscle cells. Normal cells are chosen to act as a protein factory and are transfected with the gene. The EPO protein is produced by the muscle cells and is delivered to the blood stream where it can act systemically.
The combination of injections of naked DNA and electric pulses (electroporation) is termed gene electrotransfer and has been proven to be an efficient non-viral method of transfecting genes into cells in varying tissues (for reviews see [12] [13] [14] . In vivo studies have shown that with gene electrotransfer to muscle it is possible to achieve long-term (that is, more than 1 year) expression. 15 Introducing therapeutic genes into skin is appealing because of the advantages this organ represents; it is readily accessible, can be easily evaluated and contains antigen-presenting cells, which are targets for vaccines. The skin is thus very efficient in delivering systemic immune responses after DNA vaccination by means of electroporation; [16] [17] [18] however, it would also be very interesting if the skin could serve as a 'protein factory' for therapeutic molecules on a systemic scale. Up to now gene electrotransfer to skin has been focused on creating a local transfection, either with reporter genes [19] [20] [21] [22] or with the purpose of treating of diabetic or septic wounds. 23, 24 Only one study from Maruyama et al 25 has been published using a systemic relevant compound, namely erythropoietin.
We chose to optimize gene electrotransfer to skin using EPO as a marker molecule. EPO is a 30.4 kDa glycoprotein produced in the kidney and its main role is to stimulate the erythropoiesis in the bone marrow in a number of physiological conditions. As both the EPO molecule and the end product hemoglobin are easily evaluated, EPO is a well tested compound very suitable as a model for gene electrotransfer.
In this study, we have measured systemic secretion following gene electrotransfer to skin applying relatively low amounts of DNA and the set-up used would be transferable to humans.
Results
Gene electrotransfer with EPO to mouse skin After 7 days an increase in hemoglobin was achieved in all three groups treated with intradermal EPO injection and electroporation (group A, B and C, Figure 1 ) and compared with PBS injection+electric pulses (group D) the difference was significant (Po0.05, Po0.05 and Po0.01, respectively). The increase in hemoglobin becomes more substantial after 14 days and the P-values are Po0.01, Po0.01 and Po0.05 when A, B and C are compared with plasmid injection alone (group E). The difference in hemoglobin between treated groups and controls remains significant to termination of the study ( Figure 1 ).
As expected, a significant increase in hemoglobin in the positive control (transfection with EPO to muscle) was observed after 14 days (Po0.001, Po0.001 and Po0.0001 compared with D, E and F, respectively).
There was no significant difference (P ¼ 0.65) between plasmid injection alone (group E) and PBS injection + electric pulses (group D) and there was no difference in hemoglobin levels when group D and E were compared with blank controls (group F).
Initially a dose-response relationship was observed with group C remaining on the level reached after 7 days whereas group A and B continued the increase in hemoglobin until a peak was reached after 5 weeks. Group A and B followed the same declining curve after the peak.
There was significant difference when group C (1 EPO transfection) were compared with either group B or A, (Po0.01) and when either of the transfected groups (A, B or C) were compared with any of the controls (Po0.001 to 0.0001). There was no statistical difference between group A and B.
The blood samples collected at day 0 and at the termination of the study were collected during anesthesia, which may cause hemodilution or erythrocyte sequestration and can explain the initial low hemoglobin levels and the sudden decline in all groups at the end of the study. We have observed a statistically significant difference in hemoglobin between anesthetized and nonanesthetized animals. 26 
Comparison of three different doses of EPO injections with and without electroporation
Two weeks after the transfection we found that the EPO-transfected groups (1, 2 or 3 EPO injections+electric pulses) had a statistically significant increase in hemoglobin (Po0.001, Po0.01 and Po0.0001, respectively, Student's t-test) compared with day 0, whereas all the control groups (1, 2 and 3 EPO injections alone) did not change significantly (P ¼ 0.07, P ¼ 0.47 and P ¼ 0.73, respectively). Similar statistical values were found 4 weeks after the transfection. There was no statistically significant difference between the controls.
Determination of the kinetics of serum EPO after gene electrotransfer
Four hours after initiation of the study an increase in serum EPO was observed in all the treated groups regardless of which treatment they have received ( Figure 2 ). It is likely caused by an induction of endogenous EPO excretion during the hypoxic state of the anesthesia. 27, 28 After 24 h the serum EPO level in the controls returned to baseline, whereas the group treated with EPO injections and electric pulses increased significantly (Po0.001) compared with the controls and remained significantly elevated up to a peak after 2 weeks. Eight weeks after the transfection serum EPO normalized and was similar to the controls.
In vivo bioluminescence scans of mice transfected with luciferase and EPO Figure 3 shows the result of the detection of the bioluminescence in the mice injected with luciferase (1a and 2a) and EPO plasmids (1b and 2b). Mouse 1 received subsequent electroporation and only transfection 1a (luciferase injection and electroporation) had detectable bioluminescence with an intensity level of 1168 normalized counts, NC. Luciferase injection without electroporation (2a) had an intensity level of 49 NC. EPO injection with or without electroporation (1b and 2b) did Figure 1 Gene electrotransfer with EPO to mouse skin. Fifty micrograms EPO plasmid was injected intradermally in either 1 (group C), 2 (group B) or 3 injection sites (group A) and subsequently electroporated. All three groups reached a significant difference in hemoglobin compared with i.d. plasmid injection alone, (E) which is depicted in the figure. A similar pattern of significant difference was observed when intradermal injection + electroporation (group A, B or C) was compared with PBS injection+electroporation (group D) or blank controls (group F). There was no significant difference in hemoglobin levels between plasmid injection alone (group E) and PBS injection + electric pulses (group D). N ¼ 8 in all the groups. On day 0 and day 150, blood samples were collected during anesthesia (see text). *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001. EP, electroporation.
Therapeutic levels of erythropoietin
A Gothelf et al not give any sign of transfection but had intensity levels of bioluminescence equal to non-treated areas (intensity level 6-18 NC). The combination of PBS injection and electric pulses did not differ from the background when scanned for bioluminescence (data not shown).
Bioluminescence scans of the epidermal and the subcutaneous side of skin transfected with luciferase Three days after the gene electrotransfer procedure the mice were scanned for bioluminescence after an intraperitoneal injection of luciferin ( Figure 4 ). The in vivo scan showed a mean intensity of 1283 NC. The following scan of the subcutaneous side of the skin together with the mouse, which then had a wound corresponding to the removed skin patch gave a mean intensity level of 384 NC on the subcutaneous side of the skin. The corresponding wound on the mouse had an intensity level of 18 NC, which is similar to the background intensity level. The controls had an intensity level similar to background intensity both on the epidermal side, the subcutaneous side and on the corresponding wound after removal of the skin patch.
Discussion
To our knowledge this study is the first to achieve significant increase in hemoglobin and systemic relevant levels of circulating EPO after gene electrotransfer to skin using plate electrodes and 100 mg DNA per mouse. Furthermore, we found that only 50 mg of EPO plasmid combined with electric pulses was able to induce a significant increase in hemoglobin compared with controls.
Electrical parameters

In 2001 Maruyama et al
25 transfected EPO to rat skin using three different types of electrodes. They injected up to 1600 mg of plasmid with subsequent delivery of electric pulses with either plate electrodes, two needle electrodes or a 'plate-and-fork' type of electrode in which three needles were placed in the skin parallel to the surface and the skin was sandwiched between the needles and a plate electrode. The electroporation was delivered as eight 50 ms pulses with 12-50 V between the electrodes. An increase in hemoglobin and serum EPO was only obtained with the 'plate-and-fork' electrode combined with the low voltages (12-24 V, applied voltage; the distance between the electrodes is not reported).
In our study, with plate electrodes we have achieved a higher effect, and with much lower amounts of DNA. A partial explanation could be a different pulse combination and larger field strength.
More than 35 studies have been published regarding gene electrotransfer to skin and many different pulse and electrode combinations have been successful in transfecting reporter genes into skin. Not only combinations of high voltage pulse (HV) and low voltage pulse (LV) pulses are efficient in skin as well as different kinds of tissues, 29 but also LV pulse combinations are effective in transfecting reporter genes into skin with plate electrodes. 22 
Dose and response
Initially a dose-response relationship between number of EPO transfections and increase in hemoglobin was observed, but after 5 weeks there were only small differences when two EPO injections were compared with three EPO injections. The group receiving one Only transfection 1a, which received luciferase plasmid and electroporation had detectable bioluminescence. Luciferase injection without electroporation (2a) and EPO plasmid injection with (1b) or without (2b) electroporation did not give any sign of transfection but had intensity levels equal to non-treated areas. Therapeutic levels of erythropoietin A Gothelf et al transfection remained at a borderline level of hemoglobin increase.
The evaluation of the effect of the transfection depends on the plasmid and what the purpose is. Theoretically one can presume that to achieve a paracrine/endocrine effect the dose of the plasmid can be low. A higher dose is needed if you want the local effect, which targets every single cell in the treated area, and an even higher dose is needed if a systemic effect is wanted. 10 In the latter case the transfected cells/area must have enough DNA to produce a protein, which can enter the blood stream and act systemically. This hypothesis is based on studies of gene electrotransfer to muscle and the conditions can be different for skin. The difference between borderline and significant systemic effect for EPO gene electrotransfer to mice skin lies between plasmid doses of 50-100 mg per mouse in our study. The fact that consistent significant rises in serum EPO are found after just 100 mg of DNA in the electrotransfer procedure gives hope that it might be realistic to use this strategy in patients.
Duration of expression
A great deal of research has been devoted to study the fate of recombinant human EPO (rHuEPO) in different mammals, including mice, but the pharmacokinetic and dynamic properties of mouse EPO in mice is less investigated.
Studies involving intravenous or subcutaneous injections of rHuEPO found a half-life (t 1 2 ) of circulating EPO of 3-6.9 h, 30, 31 and due to the homology of EPO between the mammalian species 32, 33 we assume that t 1 2 of mouse EPO is probably in the same range. Several studies have shown that though the maximum concentration (C max ) of serum EPO after s.c. administration is less compared with i.v. injection and with a lower bioavailability, 34, 35 the increase in plasma EPO remains elevated for a longer period after s.c. injections probably because of protracted release from the injection site to the blood flow.
We have in our study used mouse EPO plasmid and analyzed the serum contents using a mouse EPO ELISA kit, but will in the following theoretical deductions compare our data with kinetic data from human EPO in mice due to the similarities between the two species.
Thus to understand the slope of the hemoglobin curve data can be divided into three phases ( Figure 5 ):
Phase I from day 0 to day 35:. The EPO plasmid is transfected to the skin on day 0. The initial increase in serum EPO 4 h after the transfection is an endogene response provoked by the hypoxia during the anesthesia. 27, 28 It still needs to be established at which time-point the expression starts in the cell, but it is evident that after 24 h a statistically significant increase in serum EPO is observed. As a consequence of increased serum EPO the hematopoietic system is activated and it has been shown that 8 h after a single subcutaneous injection of rHuEPO to mice the bone marrow has initiated the cascade of events because of the hormone. 31 After 24 h the serum EPO levels in the control groups have returned to baseline indicating that only the combination of intradermal EPO plasmid injections and electric pulses has generated an increase in serum EPO as a result of gene transfer. EPO plasmid injections alone did not alter serum EPO levels beyond 24 h, nor did PBS injections combined with electroporation.
At day 3 an increase in hemoglobin is observed in all the groups but because of the conditions during and after the anesthesia it is difficult to distinguish between physiological effects and transfection efficacy, but it has been shown that the red blood cell count increases gradually up to 6 days after a single rHuEPO injection. 35 At day 7 the increase in hemoglobin is evident in the treated groups whereas the controls stay consistently at the baseline. The groups, which received two or three EPO transfections continue to increase up to day 35.
The t 1 2 of an EPO molecule in serum being short, approximately 3-7 h, serum EPO level correlates to the extent of expression in the skin. Serum EPO continues to increase and reaches a peak at day 14. This coincides with data from Heller et al 22 who has shown a significant increase in luciferase expression 14 days after gene electrotransfer to skin with plate electrodes and a decrease after 17 days. Once reaching the bone marrow the effect of an EPO molecule lasts 5-7 days 31 so theoretically a connection between a peak in serum EPO and a peak in hemoglobin of this kind at day 35 would be expected. 36, 37 The serum EPO level was still elevated after 6 weeks but not statistically significant, and after 8 weeks there was no difference between the treated groups and the controls.
Phase III from day 63 to day 150:. Although serum EPO in the treated groups are similar to controls after 8 weeks, an increase in hemoglobin in group A and B persists. This could be because of differences in duration of expression as observed by Hojman et al. 10 After gene electrotransfer with EPO to muscle they could divide the group into initial responders, which returned to baseline and responders in which hemoglobin stayed elevated for several months.
Our data show that the persistent elevated level of hemoglobin is due to few mice with increased hemoglobin compared with controls.
Which cells are transfected?
In the study by Maruyama et al. 25 only one electrode type (the 'plate-and-fork' electrode) combined with the low voltages (12-24 V) resulted in an increase in hemoglobin and serum EPO. The authors discuss the point, and suggest perhaps it was in fact the underlying muscle fibers in the rat skin, which were transfected and not the skin.
In studies with gene electrotransfer to pig skin, which is much thicker than mouse skin and without muscle fibers in the skin/subcutis we have achieved transfection of luciferase (Gothelf et al. 26 ). The fact that it is possible to transfect porcine skin using the same procedure, and the fact that the intradermal injections in this study were carried out with utmost care to ensure plasmid delivery in the superficial layers of the skin and to prevent subcutaneous deposits minimize the risk that our results should be due to transfection of muscle fibers. The use of plate electrodes reduces the risk as well compared with penetrating electrodes.
Transfecting genes to skin gives, compared with muscles, a short-term transfection, but our results indicate that apparently not only keratinocytes are targeted but other, longer living cell types are involved. 38 Studies involving gene electrotransfer to skin with reporter genes such as luciferase, green fluorescent protein and betagalactosidase indicate that transfection occurs in epidermis and in dermis, 21, 25, 39 but it still needs to be established as to exactly what cells are responsible for the transgene expression. It is also possible that using different electrical parameters, different cells may be transfected due to different optima for transfer based on for example, cell size and shape.
During the preparation of this article we have been working with immunohistochemical stainings of skin transfected with green fluorescent protein to provide some histological data. Unfortunately the skin itself has an abundant amount of autofluorescence, which make it difficult to distinguish between normal skin cells and transfected skin cells, despite different protocols including different antibodies. We thus conducted the study involving the bioluminescence scans of both the epidermal and the subcutaneous side of the skin to macroscopically define that the transfection is primarily in the skin and not in the subcutaneous layer.
Clinical relevance
Gene therapy is achieving increasing attention and has a wide range of possibilities to be beneficial to humans. It is important to find and optimize efficient means of transfecting the cells with a high level of safety to patients as well as for the staff handling the genes. Heller et al. 40 published in 2008 data from the first clinical trial using electroporation as a means for gene therapy. They transfected IL-12 coding plasmid to metastatic nodules Therapeutic levels of erythropoietin A Gothelf et al from malignant melanoma and found the technique safe and efficient. Although metastatic lesions are different from normal skin this study is a proof on concept that gene electrotransfer as a means of gene therapy has a possibility of entering clinical trials.
Also in improving wound repair gene electrotransfer is taking a leading part. Several studies regarding gene transfer of vascular endothelial growth factor or keratinocyte growth factor have shown increased wound healing in for example, ischemic skin flaps 41 and septic wounds. 24 Gene transfection to skin has not received the same amount of attention as for example gene transfer to muscle, probably because gene transfer to muscle is efficient and easy to perform. But skin has a number of qualities, which can be valuable in gene therapy.
The skin consists of various cell types, each with their life span, which theoretically can react with an individual kinetic profile upon transfection with a gene. Furthermore, the skin is richly vascularized, which can have importance for a possible systemic distribution and effect of the transgene. The combination of slow release and amount of circulation in the skin could be relevant to the effect of gene electrotransfer.
After gene electrotransfer with 100 mg EPO the maximum level of serum EPO of 1200 pg ml -1 was reached after 2 weeks, which corresponds to 120 mIU ml -1 . 31 Clinical studies of s.c. injections of EPO to healthy volunteers 34 have shown a C max of serum EPO of 144 mIU ml -1 after s.c. injection of 150 U kg -1 , which gave hematological response and is comparable with the serum EPO level achieved in our study.
The immunological properties make skin an excellent target for DNA vaccination. Dendritic cells as well as Langerhans cells are antigen-presenting and part of the immune surveillance system and thus interesting in the development of vaccines for example, malaria.
Gene electrotransfer has a potential in treating cancer and other systemic disorders. The perspective lies in enabling the normal cells to produce the wanted drug, which then can act systemically.
In conclusion, this study shows that it is possible to achieve significant systemic levels of a circulating protein after gene electrotransfer with non-invasive plate electrodes to mice skin. The technique is feasible and easy to administer in the clinical setting as well. This has changed the position of the skin as a potential target in gene therapy. Now, not only DNA vaccinations have a perspective but gene electrotransfer with other therapeutic genes can be relevant in finding new possibilities in treating patients and entering clinical trials.
Materials and methods
Animals
The study was performed with approval from the Danish Animal Experiments Inspectorate and in accordance with the European Convention for the Protection of Vertebrate Animals used for Experimentations. Nineweek-old female NMRI mice (own breed, Copenhagen University Hospital Herlev) were kept in a pathogen-free environment on a 12h/12h light/darkness cycle. Food and water were provided ad libitum.
Plasmid preparation
The plasmid-encoding mouse EPO was induced by the doxycycline-dependent Tet-On system. 42 For each EPO injection 50 mg of pUHD-EPO, 50 mg Tet-On and 50 mg Tet-s were diluted in 100 ml PBS (concentration 1.5 mg ml -1 ). 43 For the bioluminescence study 75 or 100 mg of the reporter gene luciferase (CMV-Luc, Promega Corporation, Madison, WI, USA) was used for gene transfection.
Plasmid purification was performed using Qiafilter Plasmid Maxiprep kits (Qiagen, Hilden, Germany) according to the manufacturer's protocol.
Electrical parameters
The electric pulses were administered with custom made plate electrodes connected to a square wave electroporator (Cliniporator, IGEA, Carpi, Italy). The plates were 15 mm long and 10 mm wide, and the distance between the plates was 3 mm. The plasmid volume was injected at the dorsolateral side of the mouse where it is possible to lift the injected skin bleb and insert it between the two electrode plates (Supplementary Figure A) . The electric pulses consisted of one HV with a voltage of 300 V (1000 V/cm) and a duration of 100 ms, and one LV with a voltage of 30 V (100 V/cm) and a duration of 400 ms. There was a 1000 ms lag between the HV and LV pulses. The electrodes were coated with electrode gel, EKO-GEL (Ekkomarine Medico, Holstebro, Denmark), to secure proper contact with the shaved skin and the electric pulses were delivered within 2 min after the plasmid injection.
Treatment protocol for gene electrotransfer of EPO to skin
All animals were anesthetized with Hypnorm (0.4 ml kg -1 , Janssen Saunderton, Buckinghamshire, England) and Dormicum (2 mg kg -1 , Roche, Basel, Switzerland) and shaved on one or both dorsolateral sides. With most care to secure intradermal injection, the plasmid was administered with a 29-G insulin syringe and the treatment delivered was A: 3 intradermal plasmid injections on different spots on the skin with subsequent electric pulses, B: 2 intradermal plasmid injections on different spots on the skin with subsequent electric pulses or C: 1 intradermal plasmid injection with subsequent electric pulses. Controls were D: intradermal PBS injection and subsequent electric pulses, E: 1 intradermal plasmid injection alone, and F: no treatment apart from the anesthesia.
In addition as a positive control, a group received an intramuscular plasmid injection (1.5 mg pUHD-EPO+1.5 mg Tet-On+1.5 mg Tet-S/20 ml PBS) and electric pulses. 10 The plasmid was injected in the right m. tibialis cranialis and the electric pulses were delivered with a 4-mm plate electrode. The applied field strength for the HV pulse was 800 V/cm, but other electric parameters were similar to the electric pulses delivered to the skin. All groups had an n ¼ 8.
To activate the transcription of EPO in the cells, all mice had 0.2 mg l -1 of doxycycline (doxycycline hyclate, Sigma Aldrich, Broendby, Denmark) added to the drinking water. 44 After 5 months the animals were terminated by exsanguination during anesthesia.
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Evaluation of the hemoglobin levels
Blood samples for hemoglobin analysis were collected from the retro-orbital sinus at day 0, 3 and 7 and from then on once every week. Hemoglobin was measured using the HemoCue Hb201+ (HemoCue, AB, Sweden).
Comparison of three different EPO plasmid injections
To validate our choice of using only 1 EPO injection (group E) as a control, an additional study was performed. We compared 1, 2 and 3 EPO plasmid injections without electric pulses to 1, 2 and 3 EPO plasmid injections with electric pulses. N was 6 for each condition. The plasmid injections were administered as previously explained and blood samples for hemoglobin measurement were collected at day 0, 14 and 28.
Kinetic study with measurement of serum EPO levels
Groups of mice received (a) 2 EPO transfections as described above, (b) two EPO injections alone without electric pulses or (c) two PBS injections with electric pulses, all groups had as a minimum N ¼ 6. Mice were anesthetized at different time points and exsanguinated to measure mouse serum EPO levels with ELISA (Quantikine ELISA kit, R&D Systems, Minneapolis, MN, USA) according to the manufacturer's protocol.
Co-transfection to skin with EPO and luciferase; subsequent detection of bioluminescence Six mice received two adjacent transfections: one intradermal injection with 50 mg EPO as described above and one intradermal injection with luciferase (75 mg/ 100 ml PBS). Three mice were in the electroporation group whereas three served as controls.
After 48 h the mice were anesthetized and received 3 mg luciferin (Promega Corporation, Madison, WI, USA) dissolved in 300 ml PBS as an intraperitoneal injection.
The mice were scanned for bioluminescence in pairs (treated animal vs control) 15 min after luciferin injection with the Optix MX-2 Optical Molecular Image System (Advanced Research Technologies, Montreal, Canada). Bioluminescence was measured in peaks of intensity in normalized counts (NC).
Bioluminescence scans of the epidermal and subcutaneous side of the skin after gene electrotransfer with luciferase
With the purpose of macroscopically detecting the location of the gene transfection in skin, mice were transfected with 100 mg (1 mg ml -1 ) of luciferase as previously described (N ¼ 4). After 3 days the mice received an intraperitoneal injection of 3 mg luciferin and were scanned in vivo for bioluminescence. Within minutes after the in vivo scan the mice was quickly euthanized by cervical dislocation. The transfected skin patch was immediately removed and the subcutaneous side of the skin was then scanned for bioluminescence. Controls were PBS injection and subsequent electric pulses (N ¼ 2) and luciferase injection alone (N ¼ 2). Supplementary Figure B shows the injected volume visualized by injection of ink.
Statistical analysis
Hemoglobin data from the gene electrotransfer to skin study was evaluated as repeated measurements and validated and analyzed with an exponential decrease model using SAS software version 9.1. 'Group', 'days' and 'mouse' were considered as factors and baseline levels of hemoglobin were used as a covariant. P-values o0.05 were considered significant.
In the study comparing three doses of EPO plasmid with and without subsequent electroporation two-sided Student's t-test was used to compare pre-treatment hemoglobin levels with post-treatment hemoglobin levels. A one-way ANOVA was used to compare the groups.
Statistical significance of difference in serum EPO was determined using two-sided Student's t-test. The error bars in Figure 2 represent s.d.
